Veit Bergendahl will assume operational responsibility for process development, clinical and commercial cGMP manufacturing, engineering and technology as well as automation in production from April 1, 2026.
Sanofi has completed its acquisition of Dynavax, adding its adult vaccines and pipeline candidates to strengthen Sanofi’s presence in adult immunization.
WuXi Biologics partners with Sinorda on bispecific antibodies for autoimmune diseases and HanchorBio on fusion proteins for oncology and immunology.
This infographic hopes to provide scientists with a comprehensive overview of fluorescence imaging strategies for extracellular vesicle research.
How CDMOs are navigating uncertainty, forging partnerships, and embracing flexibility.
Fourth major US manufacturing investment announced this year, advancing AstraZeneca’s historic $50 billion commitment to medicines manufacturing and R&D.
New state-of-the-art facility in Philadelphia provides integrated lab and collaboration space along with tailored guidance to help move advanced therapies from early research to clinical readiness.
AGC Biologics has partnered with Rarity PBC to provide development and GMP manufacturing of a gene therapy aimed at treating a rare, life-threatening immune disorder.
Novartis plans to establish a flagship manufacturing hub in North Carolina by 2027-2028 as part of a $23 billion investment in US infrastructure.
This infographic provides industry professionals and senior scientists with insights into detailed methodologies for addressing stability challenges in protein therapeutics.
SK Pharmteco has announced a $6.1 million investment to expand its Rancho Cordova, California, facility with new lab and kilo-scale capabilities for solid-phase peptide synthesis and purification.
Following the acquisition of MCE Pharma Brenntag is building a unique position in both traditional pharma and biopharma.
Fujifilm Biotechnologies has opened one of North America's largest commercial-scale cell culture biomanufacturing sites in Holly Springs, North Carolina, US.
Symeres has appointed Gabriella Gentile as Chief Operating Officer to lead global operations and drive transatlantic growth, leveraging her extensive experience in the pharmaceutical and biotech sectors.
Join us for a dynamic virtual event where science meets strategy.
Dinamiqs, a Siegfried company specialized in viral vector design and manufacturing, inaugurated its new cGMP manufacturing facility.
Merck's first climate-neutral production facility has opened at its Blarney site in Cork, Ireland. The €150 million new building is part of the group's €440 million investment program in Ireland.
Acquisition supports Roche’s strategy as it enhances the company’s portfolio in cardiovascular, renal, and metabolic diseases (CVRM) and offers optionality for future combination development.
Includes $1.2 billion in manufacturing facilities, AI, and advanced digital technologies, creating hundreds of highly skilled US jobs.
Asahi Kasei Life Science emerges as a new growth driver, uniting bioprocess solutions, CRO, and CDMO services to shape the future of healthcare under President Ken Shinomiya’s leadership.
CRDMO Symeres has acquired DGr Pharma, expanding its capabilities with DGr Pharma’s regulatory and consultancy expertise to provide more comprehensive drug development services.
Download this complimentary how-to guide today!
This Expert Insights eBook hopes to provide scientists with more information on analytical ultracentrifugation (AUC), allowing you to further your research in this field.
MSD, known as Merck & Co. in the US and Canada, recently announced it will acquire Verona Pharma, a biopharmaceutical company focused on respiratory diseases, for approximately $10 billion.
Mabion, a biotech-focused CDMO offering end-to-end services, has announced the launch of a €500,000 oncology services contest at BIO International Convention 2025.
BASF has opened a new Good Manufacturing Practice (GMP) Solution Center in Wyandotte, Michigan, to support the supply of bioprocessing ingredients and excipients for the biopharma and pharmaceutical industries.
Ecolab Life Sciences has officially opened its new US Bioprocessing Applications Laboratory in Pennsylvania.
The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.
Thermo Fisher Scientific recently announced the grand opening of its Advanced Therapies Collaboration Center (ATxCC) in Carlsbad, California, US.
NBE Therapeutics (NBE), a wholly owned subsidiary of Boehringer Ingelheim, officially opened its new ADC R&D facility in Basel.
In a move to expand its global biomanufacturing network, US biopharma Amgen is planning to invest $1 billion to build a second drug substance manufacturing facility at its US site in Holy Springs, North Carolina. This brings the company's total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.
Santa Clara, CA-based Agilent Technologies has signed a definitive agreement to acquire specialized contract development and manufacturing organization Biovectra from H.I.G. Capital in a move to expand its end-to-end biopharma solutions.
Ori Biotech a cell and gene therapy (CGT) manufacturing technology producer, recently announced the commercial launch of IRO, a next-generation platform.
The biopharmaceutical industry is experiencing a drive towards biologic products due to their promise as treatments for chronic diseases.
SK Biopharmaceuticals, a South Korean-based biotech, has announced its new strategy to propel the company towards becoming a global “big biotech.”
